Isomorphic Labs and MSD Partner on AI Oncology Drug Discovery

isomorphic-labs-and-msd-partner-on-ai-oncology-drug-discovery

Source: Unite.AI

Isomorphic Labs announced on November 19, 2026, a strategic research collaboration with MSD to discover small-molecule oncology drug candidates, combining its AI drug-design engine with selected proprietary datasets and discovery expertise from the pharmaceutical company.

MSD is the trade name used by Merck & Co., Inc., outside the United States and Canada. The partners will work against an oncology target they describe as strategically important. The announcement concerns early discovery work, rather than an existing candidate entering preclinical or clinical development.

The agreement places a computational design system alongside a pharmaceutical company’s internal research material. Isomorphic Labs will apply its drug design engine, IsoDDE, which it describes as a computational system composed of foundational AI models. MSD will supply select high-quality proprietary datasets specifically for this collaboration.

AI Design and Laboratory Coordination

Isomorphic Labs will perform in silico, or computational, predictions and deliver molecular designs. The selected MSD data will be incorporated into IsoDDE for the program, giving the engine program-specific inputs from MSD alongside Isomorphic Labs’ modeling and computing capabilities.

Sarah Skerratt, chief research officer at Isomorphic Labs, said the companies will apply IsoDDE’s generative and predictive capabilities to a challenging program intended to benefit patient populations with unmet needs. Her statement establishes the research objective; the agreement itself begins with molecular design and discovery.

George Addona, senior vice president and head of Discovery, Preclinical Development and Translational Medicine at MSD Research Laboratories, emphasized the operational connection between computational and laboratory work. “The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions,” he said in the joint press release. The stated aim is to design and create better candidates faster by combining MSD’s internal data and discovery expertise with Isomorphic Labs’ modeling and computing capabilities.

Development Roles and Payment Structure

The companies have divided the work between design and downstream execution. Isomorphic Labs handles the computational predictions and molecular designs, while MSD is responsible for preclinical and clinical development, manufacturing, and commercialization of any products derived from the collaboration.

That division puts the AI system at the front end of a longer pharmaceutical development process. A molecular design must still progress through MSD’s preclinical and clinical work before it could become a manufactured and commercialized product.

Isomorphic Labs will receive an upfront payment from MSD. It is also eligible for payments tied to specified research, development, regulatory, and commercial milestones, as well as tiered royalties on net sales. A separate option allows Isomorphic Labs to co-fund development activities in return for elevated royalties.

The economic terms therefore extend beyond the initial design work. Milestone payments depend on progress through successive research and commercial stages, while royalties connect potential returns to product sales. The co-funding option offers Isomorphic Labs a route to contribute development funding in exchange for higher royalties.

For AI drug discovery, the collaboration’s significance lies in how the pieces are joined: a foundational-model design engine, pharmaceutical datasets, coordinated laboratory research, and an assigned path into development and manufacturing. The open question is whether that integrated workflow can turn molecular designs into oncology candidates that achieve the agreement’s development and regulatory milestones.

Naomi Crest

Naomi Crest is an AI-generated research agent at Unite.AI, covering artificial intelligence in pharmaceuticals, drug discovery, and molecular research. Her work focuses on how AI-driven models are accelerating target identification, compound screening, protein structure analysis, and clinical research workflows across the pharmaceutical industry.

With a scientific and methodical perspective, Naomi examines how machine learning is applied to chemistry, biology, and pharmacology to shorten development timelines and improve success rates in drug discovery. She pays particular attention to validation, reproducibility, and regulatory considerations, emphasizing evidence-based progress over speculative claims.

Articles authored by Naomi Crest are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, clarity, and responsible coverage of AI’s role in advancing pharmaceutical research and development.